Standard BioTools Announces $30M Payment from Illumina and Sale of Mass Cytometry Unit

What Happened

• Standard BioTools (LAB) announced two related transactions in an 8-K filed July 28, 2026. On July 24, 2026, the company received approximately $30 million cash from Illumina under a Termination, Waiver and Release Agreement in exchange for waiving its 2026 earnout and terminating certain royalty and license agreements tied to SOMAmer-based products.
• On July 28, 2026, Standard BioTools entered a Share and Asset Purchase Agreement to sell its mass cytometry business to Multiplex Bio. The agreed aggregate purchase price is $5 million on a cash‑free, debt‑free basis, payable at closing entirely by a promissory note (5‑year maturity, 6% interest). Closing is subject to customary conditions, stockholder approval and completion of Standard BioTools’ pending merger with Treeline Biosciences.

Key Details

• $30 million: cash received from Illumina (July 24, 2026) for waiver of the 2026 Illumina Earnout and termination of Royalty and License Agreements.
• $5 million: base purchase price for the mass cytometry business, paid by Multiplex Bio via a promissory note (6% interest, due in 5 years); no cash at closing.
• Up to $5 million additional: contingent consideration if Multiplex Bio completes a qualifying sale above a threshold within 10 years.
• Financing and protections: Multiplex must use best efforts to obtain a senior secured working capital loan; if it cannot, Standard BioTools may provide up to $10 million in working capital at closing. The purchase agreement includes a $1 million potential termination fee and reimbursement caps for Multiplex’s out‑of‑pocket fees (up to $250,000 in staged amounts).

Why It Matters

• The $30M cash payment provides immediate liquidity and resolves uncertain future earnout and royalty receipts tied to Illumina, but it eliminates potential future revenue streams that those royalties/earnouts might have produced.
• Selling the mass cytometry business reduces Standard BioTools’ product portfolio and shifts future revenue (and risk) to Multiplex Bio; the deal structure (promissory note, contingent upside, potential company-funded working capital) means limited immediate cash proceeds and some ongoing credit/transaction risk.
• Both transactions are material to investors because they change the company’s revenue mix, cash position and future growth prospects; closing of the asset sale also depends on shareholder approval and completion of the company’s pending merger with Treeline Biosciences.